Partnerships & Mergers
-
Boehringer Ingelheim partners with Zai Lab for dual-targeting lung cancer trial
The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).
-
Alameda Healthcare to operate EAEA’s oncology unit in a USD9 million Nasr City partnership
The partnership leverages the EAEA’s scientific expertise with Alameda Healthcare’s clinical and operational capabilities to create a sustainable, patient-centered treatment hub.
-
Gan & Lee Pharmaceuticals expands Bofanglutide to South Korea with JW Pharmaceutical partnership
The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.
-
Gilead pays USD45M to secure Kymera’s unique CDK2 molecular glue for cancer
Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.
-
Stryker acquires Amplitude Vascular Systems to enter high-growth IVL market
AVS has developed the Pulse IVL system, which uses pressurised sound waves delivered through a balloon catheter to remove calcium deposits in patients with calcified peripheral artery disease (PAD).
-
AbbVie inks USD735M deal with Haisco for non-opioid NaV1.8 painkillers
The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.
-
Telix signs USD4.3 billion partnership with Regeneron to expand next-generation precision oncology
The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.
-
Roche broadens C4 Therapeutics partnership to develop DAC cancer pipeline
C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development
-
Innovaccer partners with Infinia to develop Abu Dhabi’s AI-driven healthcare core
The partnership seeks to unify healthcare data and convert it into actionable insights that healthcare providers, insurance companies, and government agencies can leverage.
-
ADPHC taps Novo Nordisk expertise to launch precision weight management program in Abu Dhabi
A central focus of the partnership is equipping family physicians and other healthcare professionals to better identify and support individuals at risk.